MiNK Therapeutics, Inc. (INKT) stock
Close on Nov 12, 2026Market cap $48.63MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $48.63M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$11.02M
- EPS, diluted
- -$2.25
- Book value per share
- -$3.18
- Diluted shares
- 5M
Trading
- Next earnings
- Dec 7, 2026 (estimated, after the close)
- Previous close
- $10.22
- Open
- $10.20
- Day's range
- $9.53 – $10.38
- Volume
- 14,707
- Average volume (20 days)
- 11,781
- Beta (5 years)
- 0.99
- 52-week range
- $8.48 – $16.93
- RSI (14 days)
- 37.9
- Volatility (1 year)
- 73.4%
- Relative volume
- 1.09×
- WACC
- 9.8%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | INKT | S&P 500 | Difference | INKT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.5% | -2.7% | −6.8 pts | ||
| 3 months | -16.1% | -1.7% | −14.4 pts | ||
| Year to date | -14.5% | +11.9% | −26.4 pts | ||
| 1 year | -30.3% | +12.0% | −42.3 pts | ||
| 3 years | -9.2% | +78.2% | −87.4 pts | -3.2% | +21.2% |
| 5 years | -94.2% | +73.2% | −167.4 pts | -43.4% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MiNK Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About MiNK Therapeutics
Biological Products, (No Diagnostic Substances)
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing allogeneic invariant natural killer T cell therapies. The company advances both native and genetically engineered cell therapies to address cancer and immune-mediated conditions, including critical pulmonary immune failure and graft-versus-host disease. Its pipeline features agenT-797, an off-the-shelf native cell therapy evaluated across solid tumors and acute respiratory distress conditions, alongside preclinical engineered programs such as MiNK-413 and MiNK-215. Target patient groups comprise individuals with refractory solid tumors, acute hypoxemic respiratory failure, severe pneumonia, and transplant recipients facing alloreactive immune complications.
Company profile, executives and historyMiNK Therapeutics stock: common questions
What is MiNK Therapeutics's stock price?
INKT closed at $9.53 on Nov 12, 2026, down 6.79% on the day. Over the past 52 weeks it traded between $8.48 and $16.93.
What is MiNK Therapeutics's market cap?
MiNK Therapeutics was worth $48.63M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is INKT's P/E ratio?
MiNK Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.25), so it has no meaningful P/E ratio.
Does MiNK Therapeutics pay a dividend?
No. MiNK Therapeutics has not paid a cash dividend over the last twelve months.
When does MiNK Therapeutics report earnings next?
MiNK Therapeutics is expected to report Q3 FY2026 results on Dec 7, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has INKT stock performed over the past year?
Including dividends, INKT returned -30.3% over the past year, against +12.0% for the S&P 500.
How many INKT shares are sold short?
0M shares were sold short at the latest FINRA report, 1.14% of the float, or 4.3 days of average trading volume.
Who are MiNK Therapeutics's competitors?
Companies most similar to MiNK Therapeutics by business, industry and size include INAB, IPSC, ALLO, TCRX, FATE.
See a number that looks wrong?